{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93","upperLimit":"97","value":"95"},{"groupId":"OG001","lowerLimit":"87","upperLimit":"95","value":"91"}]}],"title":"1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86","upperLimit":"92","value":"89"},{"groupId":"OG001","lowerLimit":"80","upperLimit":"91","value":"85"}]}],"title":"2 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77","upperLimit":"84","value":"80"},{"groupId":"OG001","lowerLimit":"72","upperLimit":"84","value":"77"}]}],"title":"3 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"156"}],"units":"Participants"}],"description":"The event is death from any cause, patients alive at the time of last observation are considered censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients","id":"OG000","title":"Auto-Auto Standard Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients","id":"OG001","title":"Auto-Allo Standard Risk"}],"paramType":"NUMBER","populationDescription":"Patients that completed second transplant","reportingStatus":"POSTED","timeFrame":"Years 1, 2, and 3","title":"Overall Survival (OS) for Standard Risk","type":"SECONDARY","unitOfMeasure":"percentage of patients"}